Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

2.

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G.

Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.

PMID:
29473209
3.

18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.

Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L.

J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. Epub 2018 Feb 1.

PMID:
29419478
4.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
5.

Increased frequencies of circulating and tumor-resident Vδ1+ T cells in patients with diffuse large B-cell lymphoma.

Reboursiere E, Gac AC, Garnier A, Salaun V, Reman O, Pham AD, Cabrera Q, Khoy K, Vilque JP, Fruchart C, Chantepie S, Johnson-Ansah H, Macro M, Cheze S, Benabed K, Mear JB, Troussard X, Damaj G, Le Mauff B, Toutirais O.

Leuk Lymphoma. 2018 Jan;59(1):187-195. doi: 10.1080/10428194.2017.1321751. Epub 2017 May 31.

PMID:
28562153
6.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

7.

The prognostic value of hematogones in patients with acute myeloid leukemia.

Chantepie SP, Parienti JJ, Salaun V, Benabed K, Cheze S, Gac AC, Johnson-Ansah H, Macro M, Damaj G, Vilque JP, Reman O.

Am J Hematol. 2016 Jun;91(6):566-70. doi: 10.1002/ajh.24350. Epub 2016 Apr 13.

8.

Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial.

Chantepie SP, Mear JB, Guittet L, Dervaux B, Marolleau JP, Jardin F, Dutheil JJ, Parienti JJ, Vilque JP, Reman O.

Trials. 2015 Nov 23;16:533. doi: 10.1186/s13063-015-1057-7.

9.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
10.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
11.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chaleteix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traullé C, Vilque JP, Pétillon MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P.

Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14. No abstract available.

12.

Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.

Chantepie SP, Reboursiere E, Mear JB, Gac AC, Salaun V, Benabed K, Cheze S, Johnsonansah H, Macro M, Vilque JP, Reman O.

Leuk Lymphoma. 2015;56(8):2326-30. doi: 10.3109/10428194.2014.986478. Epub 2015 Jan 21.

PMID:
25393676
13.

The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.

Quak E, Hovhannisyan N, Lasnon C, Fruchart C, Vilque JP, Musafiri D, Aide N.

Haematologica. 2014 Jun;99(6):e84-5. doi: 10.3324/haematol.2014.104125. Epub 2014 Feb 28. No abstract available.

14.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T.

J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.

PMID:
23109692
15.

Hematogones: a new prognostic factor for acute myeloblastic leukemia.

Chantepie SP, Salaün V, Parienti JJ, Truquet F, Macro M, Cheze S, Vilque JP, Reman O.

Blood. 2011 Jan 27;117(4):1315-8. doi: 10.1182/blood-2010-07-295378. Epub 2010 Nov 15.

16.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R.

Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25.

PMID:
20738307
17.

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group.

Haematologica. 2010 Aug;95(8):1350-7. doi: 10.3324/haematol.2009.011759. Epub 2010 Mar 10.

18.

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramée JF, Arakelyan N, Thyss A, Moluçon-Chabrot C, Delépine R, Milpied N, Colombat P, Deconinck E; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS).

Blood. 2009 Jan 29;113(5):995-1001. doi: 10.1182/blood-2008-05-160200. Epub 2008 Oct 27.

19.

Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.

Chamorey E, Gressin R, Peyrade F, Rossi JF, Lepeu G, Foussard C, Harrousseau JL, Fabbro M, Richard B, Delwail V, Maisonneuve H, Vilque JP, Thyss A.

Oncology. 2005;69(1):19-26. Epub 2005 Jul 28.

PMID:
16088231
20.

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, Escoffre-Barbe M, Maisonneuve H, Delwail V, Gressin R, Legouffe E, Vilque JP, Desablens B, Jaubert J, Ramee JF, Jenabian A, Thyss A, Le Pourhiet-Le Mevel A, Travade P, Delepine R, Colombat P; GOELAMS.

Blood. 2005 May 15;105(10):3817-23. Epub 2005 Feb 1.

21.

[Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].

Viseux V, Schoenlaub P, Danhier S, Vilque JP, Plantin P.

Ann Dermatol Venereol. 2004 Feb;131(2):204-5. French. No abstract available.

PMID:
15026752
22.

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.

Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F; France Intergroupe des Leucémies Myéloïdes Chroniques.

Leukemia. 2002 Apr;16(4):573-80.

23.

Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.

Millot F, Brice P, Philippe N, Thyss A, Demeoq F, Wetterwald M, Boccara JF, Vilque JP, Guyotat D, Guilhot J, Guilhot F.

J Pediatr Hematol Oncol. 2002 Jan;24(1):18-22.

PMID:
11902732
24.

Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha.

Michallet M, Thiébaut A, Philip I, Charrin C, Vigouroux C, Thomas X, Bilger K, Belhabri A, Guyotat D, Corront B, Salles B, Dumontet C, Péaud PY, Vilque JP, Devidas A, Fière D.

Leukemia. 2000 Dec;14(12):2064-9.

PMID:
11187894
25.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.

Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P.

Leukemia. 2000 Jun;14(6):1006-13.

PMID:
10865965
26.

[Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation].

Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P.

Rev Med Interne. 2000 Jan;21(1):30-4. French.

PMID:
10685452
27.

Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.

Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M, Guilhot F, Le Prise PY, Abgrall JF, Deconinck E, Guyotat D, Vilque JP, Casassus P, Tournilhac O, Audhuy B, Solary E.

J Clin Oncol. 2000 Feb;18(4):780-7.

PMID:
10673519
28.

[Normolipemic plane xanthomas and non-Hodgkins malignant lymphomas].

Lonceint J, Jaussaud R, Vilque JP, Bernard P, Deville JF.

Ann Med Interne (Paris). 1999 Feb;150(2):162-3. French.

PMID:
10392266
29.

Effect of chlorambucil on bone mineral density in the course of chronic lymphoid leukemia.

Leone J, Vilque JP, Jolly D, Pignon B, Blaise AM, Pennaforte JL, Eschard JP, Etienne JC.

Eur J Haematol. 1998 Aug;61(2):135-9.

PMID:
9714527
30.

Avascular necrosis of the femoral head as a complication of chronic myelogenous leukaemia.

Leone J, Vilque JP, Pignon B, Marcus C, Pennaforte JL, Eschard JP, Etienne JC.

Skeletal Radiol. 1996 Oct;25(7):696-8.

PMID:
8915061
31.

Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.

Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, Berthou C, Caillot D, Lioure B, Cahn JY, Casassus P, Sadoun A, Audhuy B, Guyotat D, Briere J, Vilque JP, Baranger L, Polin V, Berthaud P, Hurteloup P, Herve P, Harousseau JL.

Br J Haematol. 1996 Aug;94(2):333-41.

PMID:
8759894
32.

The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.

Guilhot F, Guerci A, Fiere D, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Rochant H, Najman A, Nicolini F, Colombat P, Abgrall JF, Ifrah N, Brière J, Bauters F, Navarro M, Morice P, Bordessoule D, Vilque JP, Desablens B, Tertian G, Blanc M, Chastang C, Tanzer J.

Bone Marrow Transplant. 1996 May;17 Suppl 3:S29-31. No abstract available.

PMID:
8769697
33.

[Uveitis of pseudosarcoidosic form disclosing primary cerebral lymphoma].

Léone J, Vilque JP, Thellier E, Cleenewerck N, Bernard MH, Pennaforte JL, Diebold MD, Ducasse A, Etienne JC.

Rev Med Interne. 1996;17(9):771-2. French. No abstract available.

PMID:
8959134
34.
35.

In vitro study of THP-doxorubicin retention in human leukemic cells using confocal laser microspectrofluorometry.

Pignon B, Morjani H, Vilque JP, Millot JM, Simon G, Lartigue B, Etienne JC, Potron G, Manfait M.

Leukemia. 1995 Aug;9(8):1361-7.

PMID:
7643625
36.

Erythrocyte aggregation--determination of normal values. Influence of age, sex, hormonal state, oestroprogestative treatment, haematological parameters and cigarette smoking.

Pignon B, Jolly D, Potron G, Lartigue B, Vilque JP, Nguyen P, Etienne JC, Stoltz JF.

Nouv Rev Fr Hematol. 1994 Dec;36(6):431-9.

PMID:
7753614
37.

Evaluation of the efficacy of prophylactic intravenous antibiotherapy with ceftriaxone in post-chemotherapy agranulocytic patients.

Pignon B, Thiriet L, Aubert D, Pennaforte JL, Vilque JP, Lartigue B, Jolly D, Bajolet-Laudinat O, Etienne JC.

Nouv Rev Fr Hematol. 1990;32(4):249-52.

PMID:
2290711

Supplemental Content

Loading ...
Support Center